• 3M Drug Delivery Systems announces collaboration with Panacea Pharmaceuticals, Inc. on New Cancer Vaccine

    January 10, 2017

    • ST. PAUL, MN – (Jan. 10, 2017) – Today, 3M Drug Delivery Systems announces a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. in delivering an investigational therapeutic cancer vaccine directly to the dermis via the 3M™ Hollow Microstructured Transdermal System (hMTS). The first patient in the Phase 1 clinical study has been dosed with Panacea’s innovative cancer vaccine, marking a milestone for both companies.

      “Panacea and 3M have had a great relationship and we’re excited to continue working with them,” said Silvia Perez, President and General Manager of 3M Drug Delivery Systems. “Our hollow microneedles bring a new value proposition to their work with therapeutic cancer vaccines – offering the convenience of a transdermal patch paired with a coveted high-volume, reproducible delivery capability to the dermis.”

      “Our pre-clinical studies have shown a potentially better immune response with the hMTS when compared to intramuscular dosing, and we’ve also seen good tolerability in safety studies,” said Steve Fuller, Ph.D., Chief Operating Officer for Panacea Pharmaceuticals, Inc. “Because we need to deliver a 1 mL volume of our vaccine to the dermis, 3M’s hMTS is the delivery method of choice for our therapeutic cancer vaccine project moving forward.”

      3M hMTS continues to demonstrate a number of unique benefits, including reproducible intradermal delivery, a proven ability to deliver formulations up to 2 mL with various viscosities, and better immune response for vaccines than classic intramuscular injection.

      For more information, please visit www.3m.com/mts


      About 3M Drug Delivery Systems
      3M Drug Delivery Systems partners with pharmaceutical and biotech companies to develop and manufacture pharmaceutical products using 3M's inhalation, transdermal or microneedle drug delivery technology. 3M offers a full range of feasibility, development and manufacturing capabilities to help bring products to market. Regulatory expertise, quality assurance, operations, marketed product support and other in-house resources are available for each step of the development and commercialization process. For more information, please visit www.3M.com/dds or call 1-800-643-8086.

      About 3M
      At 3M, we apply science in collaborative ways to improve lives daily. With $30 billion in sales, our 90,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNewsroom.

      3M is a trademark of 3M Company.

      Michael Gugala
      Karwoski & Courage
      (612) 342-9604

      3M Drug Delivery Systems
      3M Center, Bldg 275-3E-10
      St. Paul, MN 55144